E

Elekta

Delivers precision radiation therapy equipment

Lead Software Developer in Test

Full-Time
No salary listed
Senior
Crawley, UK
HybridFour days on-site at the Crawley headquarters and one day working from home each week.

About the job

Requirements
  • Significant experience as a Software Developer in Test, SDET, or Test Automation Engineer, including designing and owning automation frameworks.
  • Strong experience integrating automated testing into continuous integration and continuous delivery pipelines and implementing modern DevSecOps practices.
  • Ability to define and drive quality engineering strategies within a regulated or safety-critical environment.
  • Hands-on experience with Python, JavaScript or TypeScript, Cypress, Selenium, or similar automation technologies.
  • Strong leadership and mentoring skills, with the ability to influence teams and promote a shift-left testing culture.
  • Experience troubleshooting complex software quality challenges and driving continuous improvement initiatives.
  • Familiarity with Agile development methodologies.
Responsibilities
  • Lead the design, development, and evolution of automated test frameworks for complex, safety-critical software.
  • Define and implement test automation strategies that support high-quality software delivery.
  • Integrate automated testing into continuous integration and continuous delivery pipelines to improve efficiency, reliability, and release confidence.
  • Act as the technical authority for test architecture, tooling, and quality engineering best practices.
  • Collaborate with development teams, Product Owners, and architects to build scalable and testable solutions.
  • Mentor and support SDETs, test engineers, and other team members, fostering a quality-first mindset.
  • Drive continuous improvement through the adoption of new testing technologies, tools, and practices.
  • Support the investigation and resolution of complex software quality issues and contribute to long-term quality roadmaps.

About the company

Elekta specializes in precision radiation medicine, delivering devices and software that help clinicians treat cancer and brain disorders. Its core products are radiation therapy equipment (such as linear accelerators and advanced radiosurgery platforms) and treatment-planning and clinical workflow software. These tools work together: the hardware delivers targeted ionizing radiation to tumors while imaging and planning software optimize dose exactly where it is needed, then guide clinicians through the treatment workflow. Elekta differentiates itself by offering an integrated hardware-software ecosystem with a global installed base, a focus on reaching underserved markets, and ongoing services to support clinicians and facilities. The company's goal is to improve patient outcomes by expanding access to high-quality radiation therapy and growing its installed base around the world.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Stockholms kommun, Sweden

Founded

1972

Get referred to Elekta

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • August 2026 EIB financing supplies €100 million for R&D through 2029.
  • Unity Pro launched at ASTRO 2026, adding AI contouring, GPU planning, and remote collaboration.
  • China and U.S. order growth improved in 2026, supporting Elekta’s recovery into 2027.

What critics are saying

  • Elekta cut 450 jobs in 2026; execution failures can destroy promised SEK500 million savings.
  • Second-quarter 2025/26 cancellations of SEK2,197 million expose order-quality problems and backlog fragility.
  • Siemens Healthineers and Varian dominate scale; missed product cycles would shrink Elekta into irrelevance.

What makes Elekta unique

  • Elekta Unity and Evo anchor MRI-guided, adaptive radiation unavailable from most rivals.
  • Its installed base spans 120 countries, giving hospitals workflows, service, and upgrades.
  • September 2026 ASTRO data strengthen Elekta’s clinical credibility in pancreatic cancer.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

401(k) Company Match

Paid Vacation

Hybrid Work Options

Wellness Program

Tuition Reimbursement

Growth & Insights and Company News

Headcount

6 month growth

↑ 2%

1 year growth

↑ 2%

2 year growth

↑ 3%
MarketScreener
Sep 29th, 2026
Elekta presents study at ASTRO 2026 showing promising long-term results.

Elekta presents study at ASTRO 2026 showing promising long-term results. Published on 09/29/2026 at 01:23 am EDT Finwire - Translated by Marketscreener - See original Medical technology company Elekta is highlighting new study data presented at ASTRO 2026 showing promising long-term results for patients with localized pancreatic cancer who were not candidates for surgery. The study at Memorial Sloan Kettering Cancer Center included 123 patients who were treated with high-dose MR-guided adaptive radiation therapy using Elekta Unity between May 2020 and December 2024. After a median follow-up of just over two years, overall survival was 37.4 percent at two years and 26.3 percent at three years. The proportion of patients without local progression was 76.8 percent at both two and three years. The researchers believe the results warrant further evaluation of the treatment strategy. Elekta is also continuing the development of Unity through Unity Pro, which includes AI-assisted contouring, GPU-accelerated planning and remote collaboration capabilities. (C) Finwire - 2026

Definite Article Media Limited
Sep 15th, 2026
HCA expands radiotherapy capabilities with MR Linac launch.

HCA expands radiotherapy capabilities with MR Linac launch. HCA Healthcare UK (HCA UK) has expanded its radiotherapy capabilities with the introduction of the Elekta Unity MR-Linac at The Harley Street Clinic, bringing personalised radiotherapy treatment to patients and furthering its complex cancer care offering. The MR-Linac combines a high-resolution MRI scanner with a linear accelerator, enabling clinicians to visualise tumours in real time while delivering radiotherapy. This approach, known as MR-guided and adaptive radiotherapy, allows treatment to be precisely targeted, even as tumours move or change shape during a treatment session. HCA explains the technology is particularly beneficial for cancers in areas of the body that are subject to movement during a treatment, such as prostate and central lung tumours. By continuously tracking tumour motion and adapting treatment accordingly, clinicians can deliver higher radiation doses with increased accuracy, HCA said, adding this may reduce the number of treatment sessions required for some patients while protecting surrounding healthy tissue. This acquisition of this image-guided radiotherapy represents a significant investment of £15m for HCA UK and marks the organisation's first MR-Linac system globally. The Harley Street Clinic becomes one of only a small number of providers in London to offer this advanced form of radiotherapy. Treatment will be delivered by HCA UK's multi-disciplinary cancer team, including consultant clinical oncologists, physicists, dosimetrists and radiographers, who work together on treatment planning and delivery. The service will be led by dedicated MR-Linac consultant, Dr Elena Moreno Olmedo, an expert in MR-guided radiotherapy. Dr Moreno Olmedo will oversee treatment sessions, working closely with the wider team to adapt each patient's radiotherapy plan in real time to ensure optimal precision. The introduction of the technology coincides with HCA UK joining the international Elekta MR-Linac Consortium, a global collaboration of centres focused on advancing evidence-based use of MR-guided radiotherapy. The consortium aims to optimise treatment approaches, improve tumour control and survival outcomes, and enhance patient quality of life through ongoing research and shared clinical expertise. Dr John Conibear, clinical oncologist and radiotherapy lead clinician at HCA UK, said: "MR-guided radiotherapy represents a significant advancement in how Healthcare & Protection deliver precision cancer treatment. "The ability to see and respond to tumour motion in real time allows Healthcare & Protection to treat with greater accuracy and confidence, particularly for tumours that have traditionally been challenging to target. "Ultimately, this means we can deliver highly personalised care with the potential for improved outcomes and fewer treatment sessions for patients." William Pressley, CEO at The Harley Street Clinic, added: "Healthcare & Protection is proud to be one of the first independent hospitals in London to offer advanced radiotherapy with the use of the MR-Linac at The Harley Street Clinic. "The introduction of this technology reflects its continued investment in advanced cancer care and its commitment to providing patients with access to the latest treatment innovations. "This technology enables our expert teams to deliver highly precise, adaptive radiotherapy, reinforcing our position as a leading centre for complex cancer treatment."

Göteborgs-Posten
Aug 29th, 2026
Elekta secures $112M EIB loan for advanced cancer treatment research

Stockholm-based medical technology company Elekta has secured a loan of SEK 1.1 billion from the European Investment Bank to advance cancer treatment development. The funding will support research into radiation therapy and radiosurgery for various cancers and neurological diseases, including treatment software development. CFO Klara Eiritz said the financing provides flexibility to execute the company's long-term strategy whilst investing in innovations that improve treatment outcomes and patient experience. Most research will be conducted in Sweden and the Netherlands. The EIB loan covers up to half of the total investment costs.

Affärsvärlden
Aug 27th, 2026
Elekta and Boliden fall in irregular trading.

Elekta and Boliden fall in irregular trading. The Stockholm Stock Exchange has begun Thursday's trading with an uneven trend. Today 09:45 Interim reports have continued to pour in, with Elekta as the morning's heaviest company. Furthermore, Boliden is entering South America through a major acquisition. In the US, chip company Nvidia's report was well received and the stock rose nearly 5 percent in after-hours trading last night. Focus now shifts to the Federal Reserve's meeting in Jackson Hole, which begins today and ends on Saturday. Around 09.15, the OMXS30 index was down 0.08 percent to 3,323.61. Shares worth approximately SEK 1.2 billion were traded on the Stockholm Stock Exchange. Among the stock exchange's major industry sectors, technology performed best with a rise of 0.8 percent. On the other end, consumer staples were at the bottom with minus 0.6 percent. Among the leading stocks included in the OMXS30 index, Ericsson B rose 1.2 percent while ABB was up 0.5 percent. Boliden had the weakest performance with minus 2.4 percent while H&M B was down 1.3 percent. Mining company Boliden has entered an agreement to acquire Votorantim's 64.68 percent stake in Nexa Resources, a zinc and silver producer with operations in Brazil and Peru. Boliden pays with its own shares, meaning Votorantim will own 7.0 percent of the shares in Boliden. Boliden has secured bridge financing of USD 2.0 billion to support the deal. Medical technology company Elekta's adjusted operating profit in the first quarter rose to SEK 395 million, 24 percent higher than analysts' expectations of SEK 318 million. Revenue came in lower than expected while order intake was in line with consensus. The company reiterates its guidance for the current fiscal year 2026/27. However, the stock falls 3.1 percent. Consumer electronics chain Elon reports increased revenue and turns to operating profit in the second quarter compared to a loss in the same quarter last year. This is the second consecutive quarter with clear positive development. The stock surges 19 percent. Wind power company Eolus reports a sharp decrease in revenue in the second quarter compared to the same quarter last year. The operating loss decreased. The stock climbs 20 percent. Research company Saniona reports decreased revenue and increased operating loss in the second quarter compared to the same quarter last year. The stock falls 2.7 percent. Pharmaceutical company Bioinvent reports a sharp decline in revenue and turns to operating loss in the second quarter, compared to a profit in the corresponding quarter last year. The stock falls 5.1 percent. Foodservice company Nordrest increases revenue and operating profit in the second quarter compared to the same quarter last year. The stock rises 1.9 percent. Among today's analyst recommendations, SB1 Markets initiates coverage of several defense-related companies. Invisio and Mildef receive buy recommendations while Saab receives a neutral recommendation. Invisio rises 1.9 percent, Mildef gains 1.7 percent, while Saab is unchanged. Berenberg initiates coverage of engineering companies Sandvik and Epiroc, both receiving a hold recommendation. Sandvik is unchanged and Epiroc is up 0.1 percent.

FUJIFILM
Aug 27th, 2026
FUJIFILM Americas welcomes Michael J. Hartman as Vice President, General Counsel and Secretary.

FUJIFILM Americas welcomes Michael J. Hartman as Vice President, General Counsel and Secretary. VALHALLA, N.Y., August 27, 2026 - FUJIFILM Holdings America Corporation (FUJIFILM Americas) today announced the leadership appointment of Michael (Mike) J. Hartman as Vice President, General Counsel and Secretary, effective August 24. This new appointment strengthens the leadership team for FUJIFILM Americas regional headquarters, which represents more than 20 subsidiaries across the United States, Canada, Brazil, and Colombia. "We are very pleased to welcome Mike to Fujifilm's executive leadership team," said Kenya Nakashima, President, FUJIFILM Holdings America Corporation. "With 20-plus years of leading legal functions and teams for global healthcare and technology industry companies, Mike's depth of experience is impressive and will help guide the continued success of Fujifilm's broad and diverse businesses, as well as support our future expansion through both organic growth and acquisition." Most recently, Hartman served as Senior Vice President & General Counsel, Americas for Elekta, a global leader in radiation therapy and oncology software. Prior to that, he was Lead Division Attorney for the U.S. Industry Automation Division at Siemens. Earlier in his career, Hartman served as General Counsel & Chief Compliance Officer for Employease, a SaaS HRIS provider acquired by ADP. "Fujifilm's long history in imaging and its success in growing its leadership in the healthcare and technology sectors were key parts of what drew me to this role," said Hartman. "Fujifilm is a major player not only in the healthcare and life sciences fields, but in the electronic materials and business innovation industries as well. The company's diversification story is truly inspiring, and I look forward to playing a role in enabling its continued growth and transformation." Hartman received his Juris Doctor from the University of Georgia School of Law and his bachelor's degree from Virginia Tech. About Fujifilm. FUJIFILM Americas is the regional headquarters for the Americas. It is comprised of 20 group companies across North and Latin America that are engaged in the research, development, manufacture, sale and service of Fujifilm products and services. The company's portfolio represents a broad spectrum of industries including medical and life sciences, electronic materials, chemical, graphic arts, information systems, industrial products, broadcast, data storage, and photography. For more information, please visit: https://www.fujifilm.com/FUJIFILM Corporation/en/about/region. FUJIFILM Holdings Corporation, headquartered in Tokyo, leverages its depth of knowledge and proprietary core technologies to deliver innovative products and services across the globe through the four key business segments of healthcare, electronics, business innovation, and imaging with over 70,000 employees. Guided and united by its Group Purpose of "giving our world more smiles," FUJIFILM Corporation address social challenges and create a positive impact on society through its products, services, and business operations. Under its medium-term management plan, VISION2030, which ends in FY2030, FUJIFILM Corporation aspire to continue its evolution into a company that creates value and smiles for various stakeholders as a collection of global leading businesses and achieve a global revenue of 4 trillion yen (29 billion USD at an exchange rate of 140 JPY/USD). For more information, please visit: https://holdings.fujifilm.com/en/. Media contact.